Cargando…
Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of the COVID-19 pandemic. More than 274 million individuals have suffered from COVID-19 and over five million people have died from this disease so far. Therefore, there is an urgent need for therapeutic drugs. Repu...
Autores principales: | Strobelt, Romano, Adler, Julia, Paran, Nir, Yahalom-Ronen, Yfat, Melamed, Sharon, Politi, Boaz, Shulman, Ziv, Schmiedel, Dominik, Shaul, Yosef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984672/ https://www.ncbi.nlm.nih.gov/pubmed/35388061 http://dx.doi.org/10.1038/s41598-022-09664-1 |
Ejemplares similares
-
Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus
por: Vitner, Einat B., et al.
Publicado: (2021) -
Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection
por: Tamir, Hadas, et al.
Publicado: (2022) -
Modeling SARS-CoV-2 Infection in Mice Using Lentiviral hACE2 Vectors Infers Two Modes of Immune Responses to SARS-CoV-2 Infection
por: Katzman, Chaja, et al.
Publicado: (2021) -
Identification of T-Cell Epitopes Using a Combined In-Silico and Experimental Approach in a Mouse Model for SARS-CoV-2
por: Erez, Noam, et al.
Publicado: (2023) -
The Transmembrane Protease Serine 2 (TMPRSS2) Non-Protease Domains Regulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike-Mediated Virus Entry
por: Strobelt, Romano, et al.
Publicado: (2023)